摘要
目的：探讨利培酮与奋乃静治疗老年期精神分裂症的临床疗效和安全性。方法将60例老年期精神分裂症患者随机分为两组，每组30例，研究组口服利培酮治疗，对照组口服奋乃静治疗，观察24周。于治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前呈持续性下降（P＜0．05或0．01），研究组治疗第1周末阳性与阴性症状量表总分及阳性症状、精神病理因子分显著低于对照组（ P＜0．05或0．01），治疗第24周末仍显著低于对照组（ P＜0．01）。研究组不良反应发生率为13．3％，对照组为36．7％，研究组不良反应发生率显著低于对照组（χ^2＝4．36，P＜0．05）。结论利培酮和奋乃静均能有效改善老年期精神分裂症患者的各种精神症状，但利培酮起效快，疗效显著，安全性高，更适合老年期精神分裂症的治疗。
Objective To explore the efficacy and safety of risperidone and perphenazine in the treatment of senile schizophrenia .Methods Sixty senile schizophrenics were randomly assigned to two groups of 30 ones each ,research group took orally risperidone and control group did perphenazine for 24 weeks .Before and after treatment efficacies were assessed with the Positive and Negative Symptom Scale （TESS） and ad‐verse reactions with the Treatment Emergent Symptom Scale （TESS） .Results After treatment the total and each factor scores of the PANSS of both groups lowered continuously （P〈0 .05 or 0 .01） ,at the end of the 1st week the total ,positive symptom and psychotic score were significantly lower in research than in control group （P〈0 .05 or 0 .01） ,and so were those at the end of the 24th （P〈0 .01） .The incidence of ad‐verse reactions was respectively 13 .3% in research and 36 .7% in control group ,the former significantly lower than the latter （χ^2 =4 .36 ,P〈0 .05） .Conclusion Both risperidone and perphenazine could effec‐tively improve various kinds of mental symptoms of senile schizophrenics ,but the former takes effect more rapidly ,has an evident effect and higher safety ,and is more suitable for senile schizophrenia .
出处
《临床心身疾病杂志》
CAS
2015年第4期53-54,67,共3页
Journal of Clinical Psychosomatic Diseases
